Lung cancer is the leading cause of cancer-associated mortality worldwide1. Here we analysed 1,644 tumour regions sampled at surgery or during follow-up from the first 421 patients with non-small cell lung cancer prospectively enrolled into the TRACERx study. This project aims to decipher lung ...
The global burden of lung cancer: current status and future trends Article 21 July 2023 Lung cancer in never smokers (LCINS): development of a UK national research strategy Article Open access 20 July 2023 References Siegel, R. L., Miller, K. D., Wagle, N. S. & Jemal, A. C...
The audit, which was called the National Lung Cancer Audit, found that lung cancer treatment quality has improved, that the quality of lung cancer treatment in the United Kingdom varies between different hospitals and that lung cancer treatment in the country is not as good as treatments that ...
Reddy's Laboratories launched Versavo, a biosimilar of Roche's Avastin, in the UK. This cancer treatment drug was indicated for various cancers, including metastatic colorectal and lung cancers, among others, according to a regulatory filing. In May 2024, the FDA approved Imdelltra™ (Tar...
Camidge and Cetnar Revisit ASCO 2023 Data in Lung Cancer Reuss Reviews the Development of LP-300 in Advanced NSCLCLatest CME Events & Activities 26th Annual International Lung Cancer Congress® July 25-26, 2025 Register Now! Show Me the Data™: Bridging Clinical Gaps Along the Continuum Fr...
The lung cancer therapeutics market size is forecast to increase by USD 10.53 billion at a CAGR of 7.69% between 2023 and 2028. The market is experiencing significant growth, driven by the increasing adoption of precision medicine and research and development (RD) initiatives. The market is witne...
A new study funded by Cancer Research UK has shown that a personalised blood test can be used to identify the risk of lung cancer returning.
Image:Smoking causes 72% of all lung cancers, according to Cancer Research UK. File pic However, the LungVax provides a "really important step forward" into a future where cancer is more preventable, Michelle Mitchell, chief executive of the charity, said. ...
CA Cancer J. Clin. 73, 17–48 (2023). Article PubMed Google Scholar Wang, Y. et al. Survival trends among patients with metastatic non-small cell lung cancer before and after the approval of immunotherapy in the United States: a Surveillance, Epidemiology, and End Results database-based...
Metastatic disease is responsible for the majority of cancer-related deaths1. We report the longitudinal evolutionary analysis of 126 non-small cell lung cancer (NSCLC) tumours from 421 prospectively recruited patients in TRACERx who developed metas